\BOOKMARK [1][-]{chapter*.3}{Glossary}{}% 1
\BOOKMARK [0][-]{section*.4}{Glossary}{}% 2
\BOOKMARK [1][-]{chapter*.5}{Acronyms}{section*.4}% 3
\BOOKMARK [0][-]{section*.6}{Acronyms}{}% 4
\BOOKMARK [0][-]{chapter.1}{Introduction}{}% 5
\BOOKMARK [1][-]{section.1.1}{Cancer Research in the Post-Genomic Era}{chapter.1}% 6
\BOOKMARK [2][-]{subsection.1.1.1}{Cancer as a Global Health Concern}{section.1.1}% 7
\BOOKMARK [3][-]{subsubsection.1.1.1.1}{Genetics and Molecular Biology in Cancers}{subsection.1.1.1}% 8
\BOOKMARK [2][-]{subsection.1.1.2}{The Human Genome Revolution}{section.1.1}% 9
\BOOKMARK [3][-]{subsubsection.1.1.2.1}{The First Human Genome Sequence}{subsection.1.1.2}% 10
\BOOKMARK [3][-]{subsubsection.1.1.2.2}{Impact of Genomics}{subsection.1.1.2}% 11
\BOOKMARK [2][-]{subsection.1.1.3}{Technologies to Enable Genetics Research}{section.1.1}% 12
\BOOKMARK [3][-]{subsubsection.1.1.3.1}{DNA Sequencing and Genotyping Technologies}{subsection.1.1.3}% 13
\BOOKMARK [3][-]{subsubsection.1.1.3.2}{Microarrays and Quantitative Technologies}{subsection.1.1.3}% 14
\BOOKMARK [3][-]{subsubsection.1.1.3.3}{Massively Parallel ``Next Generation'' Sequencing}{subsection.1.1.3}% 15
\BOOKMARK [4][-]{subsubsubsection.1.1.3.3.1}{Molecular Profiling with Genomics Technology}{subsubsection.1.1.3.3}% 16
\BOOKMARK [4][-]{subsubsubsection.1.1.3.3.2}{Sequencing Technologies}{subsubsection.1.1.3.3}% 17
\BOOKMARK [3][-]{subsubsection.1.1.3.4}{Bioinformatics as Interdisciplinary Genomic Analysis}{subsection.1.1.3}% 18
\BOOKMARK [2][-]{subsection.1.1.4}{Follow-up Large-Scale Genomics Projects}{section.1.1}% 19
\BOOKMARK [2][-]{subsection.1.1.5}{Cancer Genomes}{section.1.1}% 20
\BOOKMARK [3][-]{subsubsection.1.1.5.1}{The Cancer Genome Atlas Project}{subsection.1.1.5}% 21
\BOOKMARK [4][-]{subsubsubsection.1.1.5.1.1}{Findings from Cancer Genomes}{subsubsection.1.1.5.1}% 22
\BOOKMARK [4][-]{subsubsubsection.1.1.5.1.2}{Genomic Comparisons Across Cancer Tissues}{subsubsection.1.1.5.1}% 23
\BOOKMARK [4][-]{subsubsubsection.1.1.5.1.3}{Cancer Genomic Data Resources}{subsubsection.1.1.5.1}% 24
\BOOKMARK [2][-]{subsection.1.1.6}{Genomic Cancer Medicine}{section.1.1}% 25
\BOOKMARK [3][-]{subsubsection.1.1.6.1}{Cancer Genes and Driver Mutations}{subsection.1.1.6}% 26
\BOOKMARK [3][-]{subsubsection.1.1.6.2}{Personalised or Precision Cancer Medicine}{subsection.1.1.6}% 27
\BOOKMARK [4][-]{subsubsubsection.1.1.6.2.1}{Molecular Diagnostics and Pan-Cancer Medicine}{subsubsection.1.1.6.2}% 28
\BOOKMARK [3][-]{subsubsection.1.1.6.3}{Targeted Therapeutics and Pharmacogenomics}{subsection.1.1.6}% 29
\BOOKMARK [4][-]{subsubsubsection.1.1.6.3.1}{Targeting Oncogenic Driver Mutations}{subsubsection.1.1.6.3}% 30
\BOOKMARK [3][-]{subsubsection.1.1.6.4}{Systems and Network Biology}{subsection.1.1.6}% 31
\BOOKMARK [4][-]{subsubsubsection.1.1.6.4.1}{ Network Medicine, and Polypharmacology}{subsubsection.1.1.6.4}% 32
\BOOKMARK [1][-]{section.1.2}{A Synthetic Lethal Approach to Cancer Medicine}{chapter.1}% 33
\BOOKMARK [2][-]{subsection.1.2.1}{Synthetic Lethal Genetic Interactions}{section.1.2}% 34
\BOOKMARK [2][-]{subsection.1.2.2}{Synthetic Lethal Concepts in Genetics}{section.1.2}% 35
\BOOKMARK [2][-]{subsection.1.2.3}{Studies of Synthetic Lethality}{section.1.2}% 36
\BOOKMARK [3][-]{subsubsection.1.2.3.1}{Synthetic Lethal Pathways and Networks}{subsection.1.2.3}% 37
\BOOKMARK [4][-]{subsubsubsection.1.2.3.1.1}{Evolution of Synthetic Lethality}{subsubsection.1.2.3.1}% 38
\BOOKMARK [2][-]{subsection.1.2.4}{Synthetic Lethal Concepts in Cancer}{section.1.2}% 39
\BOOKMARK [2][-]{subsection.1.2.5}{Clinical Impact of Synthetic Lethality in Cancer}{section.1.2}% 40
\BOOKMARK [2][-]{subsection.1.2.6}{High-throughput Screening for Synthetic Lethality}{section.1.2}% 41
\BOOKMARK [3][-]{subsubsection.1.2.6.1}{Synthetic Lethal Screens}{subsection.1.2.6}% 42
\BOOKMARK [2][-]{subsection.1.2.7}{Computational Prediction of Synthetic Lethality}{section.1.2}% 43
\BOOKMARK [3][-]{subsubsection.1.2.7.1}{Bioinformatics Approaches to Genetic Interactions}{subsection.1.2.7}% 44
\BOOKMARK [3][-]{subsubsection.1.2.7.2}{Comparative Genomics}{subsection.1.2.7}% 45
\BOOKMARK [3][-]{subsubsection.1.2.7.3}{Analysis and Modelling of Protein Data}{subsection.1.2.7}% 46
\BOOKMARK [3][-]{subsubsection.1.2.7.4}{Differential Gene Expression}{subsection.1.2.7}% 47
\BOOKMARK [3][-]{subsubsection.1.2.7.5}{Data Mining and Machine Learning}{subsection.1.2.7}% 48
\BOOKMARK [3][-]{subsubsection.1.2.7.6}{Bimodality}{subsection.1.2.7}% 49
\BOOKMARK [3][-]{subsubsection.1.2.7.7}{Rationale for Further Development}{subsection.1.2.7}% 50
\BOOKMARK [1][-]{section.1.3}{E-cadherin as a Synthetic Lethal Target}{chapter.1}% 51
\BOOKMARK [2][-]{subsection.1.3.1}{The CDH1 gene and it's Biological Functions}{section.1.3}% 52
\BOOKMARK [3][-]{subsubsection.1.3.1.1}{Cytoskeleton}{subsection.1.3.1}% 53
\BOOKMARK [3][-]{subsubsection.1.3.1.2}{Extracellular and Tumour Micro-Environment}{subsection.1.3.1}% 54
\BOOKMARK [3][-]{subsubsection.1.3.1.3}{Cell-Cell Adhesion and Signalling}{subsection.1.3.1}% 55
\BOOKMARK [2][-]{subsection.1.3.2}{CDH1 as a Tumour \(and Invasion\) Suppressor}{section.1.3}% 56
\BOOKMARK [3][-]{subsubsection.1.3.2.1}{Breast Cancers and Invasion}{subsection.1.3.2}% 57
\BOOKMARK [2][-]{subsection.1.3.3}{Hereditary Diffuse Gastric Cancer and Lobular Breast Cancer}{section.1.3}% 58
\BOOKMARK [2][-]{subsection.1.3.4}{Somatic Mutations}{section.1.3}% 59
\BOOKMARK [3][-]{subsubsection.1.3.4.1}{Mutation Rate}{subsection.1.3.4}% 60
\BOOKMARK [3][-]{subsubsection.1.3.4.2}{Co-occurring Mutations}{subsection.1.3.4}% 61
\BOOKMARK [2][-]{subsection.1.3.5}{Models of CDH1 loss in cell lines}{section.1.3}% 62
\BOOKMARK [1][-]{section.1.4}{Summary and Research Direction of Thesis}{chapter.1}% 63
\BOOKMARK [0][-]{chapter.2}{Methods and Resources}{}% 64
\BOOKMARK [1][-]{section.2.1}{Bioinformatics Resources for Genomics Research}{chapter.2}% 65
\BOOKMARK [2][-]{subsection.2.1.1}{Public Data and Software Packages}{section.2.1}% 66
\BOOKMARK [3][-]{subsubsection.2.1.1.1}{Cancer Genome Atlas Data}{subsection.2.1.1}% 67
\BOOKMARK [3][-]{subsubsection.2.1.1.2}{Reactome and Annotation Data}{subsection.2.1.1}% 68
\BOOKMARK [1][-]{section.2.2}{Data Handling}{chapter.2}% 69
\BOOKMARK [2][-]{subsection.2.2.1}{Normalisation}{section.2.2}% 70
\BOOKMARK [2][-]{subsection.2.2.2}{Sample Triage}{section.2.2}% 71
\BOOKMARK [2][-]{subsection.2.2.3}{Metagenes and the Singular Value Decomposition}{section.2.2}% 72
\BOOKMARK [3][-]{subsubsection.2.2.3.1}{Candidate Triage and Integration with Screen Data}{subsection.2.2.3}% 73
\BOOKMARK [1][-]{section.2.3}{Techniques}{chapter.2}% 74
\BOOKMARK [2][-]{subsection.2.3.1}{Statistical Procedures and Tests}{section.2.3}% 75
\BOOKMARK [2][-]{subsection.2.3.2}{Gene Set Over-representation Analysis}{section.2.3}% 76
\BOOKMARK [2][-]{subsection.2.3.3}{Clustering}{section.2.3}% 77
\BOOKMARK [2][-]{subsection.2.3.4}{Heatmap}{section.2.3}% 78
\BOOKMARK [2][-]{subsection.2.3.5}{Modeling and Simulations}{section.2.3}% 79
\BOOKMARK [3][-]{subsubsection.2.3.5.1}{Receiver Operating Characteristic \(Performance\)}{subsection.2.3.5}% 80
\BOOKMARK [2][-]{subsection.2.3.6}{Resampling Analysis}{section.2.3}% 81
\BOOKMARK [1][-]{section.2.4}{Pathway Structure Methods}{chapter.2}% 82
\BOOKMARK [2][-]{subsection.2.4.1}{Network and Graph Analysis}{section.2.4}% 83
\BOOKMARK [2][-]{subsection.2.4.2}{Sourcing Graph Structure Data}{section.2.4}% 84
\BOOKMARK [2][-]{subsection.2.4.3}{Constructing Pathway Subgraphs}{section.2.4}% 85
\BOOKMARK [2][-]{subsection.2.4.4}{Network Analysis Metrics}{section.2.4}% 86
\BOOKMARK [1][-]{section.2.5}{Implementation}{chapter.2}% 87
\BOOKMARK [2][-]{subsection.2.5.1}{Computational Resources and Linux Utilities}{section.2.5}% 88
\BOOKMARK [2][-]{subsection.2.5.2}{R Language and Packages}{section.2.5}% 89
\BOOKMARK [2][-]{subsection.2.5.3}{High Performance and Parallel Computing}{section.2.5}% 90
\BOOKMARK [0][-]{chapter.3}{Methods Developed During Thesis}{}% 91
\BOOKMARK [1][-]{section.3.1}{A Synthetic Lethal Detection Methodology}{chapter.3}% 92
\BOOKMARK [1][-]{section.3.2}{Synthetic Lethal Simulation and Modelling}{chapter.3}% 93
\BOOKMARK [2][-]{subsection.3.2.1}{A Model of Synthetic Lethality in Expression Data}{section.3.2}% 94
\BOOKMARK [2][-]{subsection.3.2.2}{Simulation Procedure}{section.3.2}% 95
\BOOKMARK [1][-]{section.3.3}{Detecting Simulated Synthetic Lethal Partners}{chapter.3}% 96
\BOOKMARK [2][-]{subsection.3.3.1}{Binomial Simulation of Synthetic lethality}{section.3.3}% 97
\BOOKMARK [2][-]{subsection.3.3.2}{Multivariate Normal Simulation of Synthetic lethality}{section.3.3}% 98
\BOOKMARK [3][-]{subsubsection.3.3.2.1}{Multivariate Normal Simulation with Correlated Genes}{subsection.3.3.2}% 99
\BOOKMARK [3][-]{subsubsection.3.3.2.2}{Specificity with Query-Correlated Pathways}{subsection.3.3.2}% 100
\BOOKMARK [4][-]{subsubsubsection.3.3.2.2.1}{Importance of Directional Testing}{subsubsection.3.3.2.2}% 101
\BOOKMARK [1][-]{section.3.4}{Graph Structure Methods}{chapter.3}% 102
\BOOKMARK [2][-]{subsection.3.4.1}{Upstream and Downstream Gene Detection}{section.3.4}% 103
\BOOKMARK [3][-]{subsubsection.3.4.1.1}{Permutation Analysis for Statistical Significance}{subsection.3.4.1}% 104
\BOOKMARK [3][-]{subsubsection.3.4.1.2}{Ranking Based on Biological Context}{subsection.3.4.1}% 105
\BOOKMARK [2][-]{subsection.3.4.2}{Simulating Gene Expression from Graph Structures}{section.3.4}% 106
\BOOKMARK [1][-]{section.3.5}{Customised Functions and Packages Developed}{chapter.3}% 107
\BOOKMARK [2][-]{subsection.3.5.1}{Synthetic Lethal Interaction Prediction Tool}{section.3.5}% 108
\BOOKMARK [2][-]{subsection.3.5.2}{Data Visualisation}{section.3.5}% 109
\BOOKMARK [2][-]{subsection.3.5.3}{Extensions to the iGraph Package}{section.3.5}% 110
\BOOKMARK [3][-]{subsubsection.3.5.3.1}{Sampling Simulated Data from Graph Structures}{subsection.3.5.3}% 111
\BOOKMARK [3][-]{subsubsection.3.5.3.2}{Plotting Directed Graph Structures}{subsection.3.5.3}% 112
\BOOKMARK [3][-]{subsubsection.3.5.3.3}{Computing Information Centrality}{subsection.3.5.3}% 113
\BOOKMARK [3][-]{subsubsection.3.5.3.4}{Testing Pathway Structure with Permutation Testing}{subsection.3.5.3}% 114
\BOOKMARK [3][-]{subsubsection.3.5.3.5}{Metapackage to Install iGraph Functions}{subsection.3.5.3}% 115
\BOOKMARK [0][-]{chapter.4}{Synthetic Lethal Analysis of Gene Expression Data}{}% 116
\BOOKMARK [1][-]{section.4.1}{Synthetic lethal genes in breast cancer}{chapter.4}% 117
\BOOKMARK [2][-]{subsection.4.1.1}{Synthetic lethal pathways in breast cancer}{section.4.1}% 118
\BOOKMARK [2][-]{subsection.4.1.2}{Expression profiles of synthetic lethal partners}{section.4.1}% 119
\BOOKMARK [3][-]{subsubsection.4.1.2.1}{Subgroup pathway analysis}{subsection.4.1.2}% 120
\BOOKMARK [1][-]{section.4.2}{Comparison of synthetic lethal gene candidates}{chapter.4}% 121
\BOOKMARK [2][-]{subsection.4.2.1}{Comparison with siRNA screen candidates}{section.4.2}% 122
\BOOKMARK [3][-]{subsubsection.4.2.1.1}{Comparison with correlation}{subsection.4.2.1}% 123
\BOOKMARK [3][-]{subsubsection.4.2.1.2}{Comparison with viability}{subsection.4.2.1}% 124
\BOOKMARK [3][-]{subsubsection.4.2.1.3}{Comparison with secondary screen siRNA screen candidates}{subsection.4.2.1}% 125
\BOOKMARK [3][-]{subsubsection.4.2.1.4}{Comparison of screen at pathway level}{subsection.4.2.1}% 126
\BOOKMARK [4][-]{subsubsubsection.4.2.1.4.1}{Resampling of genes for pathway enrichment}{subsubsection.4.2.1.4}% 127
\BOOKMARK [1][-]{section.4.3}{Metagene Analysis}{chapter.4}% 128
\BOOKMARK [2][-]{subsection.4.3.1}{Pathway expression}{section.4.3}% 129
\BOOKMARK [2][-]{subsection.4.3.2}{Somatic mutation}{section.4.3}% 130
\BOOKMARK [2][-]{subsection.4.3.3}{Mutation locus}{section.4.3}% 131
\BOOKMARK [2][-]{subsection.4.3.4}{Synthetic lethal metagenes}{section.4.3}% 132
\BOOKMARK [1][-]{section.4.4}{Replication in stomach cancer}{chapter.4}% 133
\BOOKMARK [2][-]{subsection.4.4.1}{Synthetic Lethal Genes and Pathways}{section.4.4}% 134
\BOOKMARK [2][-]{subsection.4.4.2}{Synthetic Lethal Expression Profiles}{section.4.4}% 135
\BOOKMARK [2][-]{subsection.4.4.3}{Comparison to Primary Screen}{section.4.4}% 136
\BOOKMARK [3][-]{subsubsection.4.4.3.1}{Resampling Analysis}{subsection.4.4.3}% 137
\BOOKMARK [2][-]{subsection.4.4.4}{Metagene Analysis}{section.4.4}% 138
\BOOKMARK [1][-]{section.4.5}{Global Synthetic Lethality}{chapter.4}% 139
\BOOKMARK [2][-]{subsection.4.5.1}{Hub Genes}{section.4.5}% 140
\BOOKMARK [2][-]{subsection.4.5.2}{Hub Pathways}{section.4.5}% 141
\BOOKMARK [1][-]{section.4.6}{Replication in cell line encyclopaedia}{chapter.4}% 142
\BOOKMARK [1][-]{section.4.7}{Discussion}{chapter.4}% 143
\BOOKMARK [2][-]{subsection.4.7.1}{Strengths of the SLIPT Methodology}{section.4.7}% 144
\BOOKMARK [2][-]{subsection.4.7.2}{Syntheic Lethal Pathways for E-cadherin}{section.4.7}% 145
\BOOKMARK [2][-]{subsection.4.7.3}{Replication and Validation}{section.4.7}% 146
\BOOKMARK [3][-]{subsubsection.4.7.3.1}{Integration with siRNA Screening}{subsection.4.7.3}% 147
\BOOKMARK [3][-]{subsubsection.4.7.3.2}{Replication across Tissues and Cell lines}{subsection.4.7.3}% 148
\BOOKMARK [1][-]{section.4.8}{Summary}{chapter.4}% 149
\BOOKMARK [0][-]{chapter.5}{Synthetic Lethal Pathway Structure}{}% 150
\BOOKMARK [1][-]{section.5.1}{Synthetic lethal genes in synthetic lethal pathways}{chapter.5}% 151
\BOOKMARK [1][-]{section.5.2}{Centrality and connectivity of synthetic lethal genes}{chapter.5}% 152
\BOOKMARK [1][-]{section.5.3}{Upstream or downstream synthetic lethal candidates}{chapter.5}% 153
\BOOKMARK [1][-]{section.5.4}{Hierachical approach}{chapter.5}% 154
\BOOKMARK [1][-]{section.5.5}{Discussion}{chapter.5}% 155
\BOOKMARK [1][-]{section.5.6}{Conclusion}{chapter.5}% 156
\BOOKMARK [0][-]{chapter.6}{Simulation and Modeling of Synthetic Lethal Pathways}{}% 157
\BOOKMARK [1][-]{section.6.1}{Simulations and Modelling Synthetic Lethality in Expression Data}{chapter.6}% 158
\BOOKMARK [1][-]{section.6.2}{Simulations over simple graph structures}{chapter.6}% 159
\BOOKMARK [2][-]{subsection.6.2.1}{Performance}{section.6.2}% 160
\BOOKMARK [2][-]{subsection.6.2.2}{Synthetic lethality across graph stuctures}{section.6.2}% 161
\BOOKMARK [2][-]{subsection.6.2.3}{Performance with inhibition links}{section.6.2}% 162
\BOOKMARK [2][-]{subsection.6.2.4}{Performance with 20,000 genes}{section.6.2}% 163
\BOOKMARK [1][-]{section.6.3}{Simulations over pathway-based graphs}{chapter.6}% 164
\BOOKMARK [1][-]{section.6.4}{Comparing methods}{chapter.6}% 165
\BOOKMARK [2][-]{subsection.6.4.1}{SLIPT and Chi-Squared}{section.6.4}% 166
\BOOKMARK [3][-]{subsubsection.6.4.1.1}{Correlated query genes}{subsection.6.4.1}% 167
\BOOKMARK [2][-]{subsection.6.4.2}{Correlation}{section.6.4}% 168
\BOOKMARK [2][-]{subsection.6.4.3}{Bimodality with BiSEp}{section.6.4}% 169
\BOOKMARK [0][-]{chapter.7}{Discussion}{}% 170
\BOOKMARK [1][-]{section.7.1}{Significance}{chapter.7}% 171
\BOOKMARK [1][-]{section.7.2}{Future Directions}{chapter.7}% 172
\BOOKMARK [1][-]{section.7.3}{Conclusion}{chapter.7}% 173
\BOOKMARK [0][-]{chapter.8}{Conclusion}{}% 174
\BOOKMARK [0][-]{chapter.8}{References}{}% 175
\BOOKMARK [0][-]{appendix.A}{Sample Quality}{}% 176
\BOOKMARK [1][-]{section.A.1}{Sample Correlation}{appendix.A}% 177
\BOOKMARK [1][-]{section.A.2}{Replicate Samples in TCGA Breast}{appendix.A}% 178
\BOOKMARK [0][-]{appendix.B}{Software Used for Thesis}{}% 179
\BOOKMARK [0][-]{appendix.C}{Secondary Screen Data}{}% 180
\BOOKMARK [0][-]{appendix.D}{Mutation Analysis in Breast Cancer}{}% 181
\BOOKMARK [1][-]{section.D.1}{Synthetic Lethal Genes and Pathways}{appendix.D}% 182
\BOOKMARK [1][-]{section.D.2}{Synthetic Lethal Expression Profiles}{appendix.D}% 183
\BOOKMARK [1][-]{section.D.3}{Comparison to Primary Screen}{appendix.D}% 184
\BOOKMARK [2][-]{subsection.D.3.1}{Resampling Analysis}{section.D.3}% 185
\BOOKMARK [1][-]{section.D.4}{Compare SLIPT genes}{appendix.D}% 186
\BOOKMARK [1][-]{section.D.5}{Metagene Analysis}{appendix.D}% 187
\BOOKMARK [1][-]{section.D.6}{Mutation Variation}{appendix.D}% 188
\BOOKMARK [2][-]{subsection.D.6.1}{Mutation Frequency}{section.D.6}% 189
\BOOKMARK [2][-]{subsection.D.6.2}{PI3K Mutation Expression}{section.D.6}% 190
\BOOKMARK [0][-]{appendix.E}{Metagene Expression Profiles}{}% 191
\BOOKMARK [0][-]{appendix.F}{Stomach Expression Analysis}{}% 192
\BOOKMARK [1][-]{section.F.1}{Synthetic Lethal Genes and Pathways}{appendix.F}% 193
\BOOKMARK [1][-]{section.F.2}{Comparison to Primary Screen}{appendix.F}% 194
\BOOKMARK [2][-]{subsection.F.2.1}{Resampling Analysis}{section.F.2}% 195
\BOOKMARK [1][-]{section.F.3}{Metagene Analysis}{appendix.F}% 196
\BOOKMARK [0][-]{appendix.G}{Stomach Mutation Analysis}{}% 197
\BOOKMARK [1][-]{section.G.1}{Synthetic Lethal Genes and Pathways}{appendix.G}% 198
\BOOKMARK [1][-]{section.G.2}{Synthetic Lethal Expression Profiles}{appendix.G}% 199
\BOOKMARK [1][-]{section.G.3}{Comparison to Primary Screen}{appendix.G}% 200
\BOOKMARK [2][-]{subsection.G.3.1}{Resampling Analysis}{section.G.3}% 201
\BOOKMARK [1][-]{section.G.4}{Metagene Analysis}{appendix.G}% 202
\BOOKMARK [0][-]{appendix.H}{Global Synthetic Lethality in Stomach Cancer}{}% 203
\BOOKMARK [1][-]{section.H.1}{Hub Genes}{appendix.H}% 204
\BOOKMARK [1][-]{section.H.2}{Hub Pathways}{appendix.H}% 205
\BOOKMARK [0][-]{appendix.I}{Replication in cell line encyclopaedia}{}% 206
\BOOKMARK [0][-]{appendix.J}{Synthetic Lethal Genes in Pathways}{}% 207
\BOOKMARK [0][-]{appendix.K}{Pathway Connectivity for Mutation SLIPT}{}% 208
\BOOKMARK [0][-]{appendix.L}{Pathway Structure for Mutation SLIPT}{}% 209
\BOOKMARK [0][-]{appendix.M}{Information Centrality for Gene Essentiality}{}% 210
